Travoprost + Timolol eye drops, solution (DuoTrav)

Phase 3

Alcon Research (ALC)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Glaucoma

ALCOX.PANCX 470

View Full Landscape

Drug Information

Target Indication

Glaucoma

Clinical Trial

NCT00333125

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/23/2006

DuoTrav

Decrease of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

ALC

Alcon Research

Ophthalmic Goods•Europe•NASDAQ

Related Pipeline

Ofloxacin otic solutionPhase 3

Acute Otitis Media

Travoprost/Timolol maleate ophthalmicPhase 3

Glaucoma, Open-angle

Optifree ReplenishPhase 3

Myopia

AL-4943A ophthalmic solutionPhase 3

Allergic Conjunctivitis

Brinzolamide ophthalmicPhase 3

Open-Angle Glaucoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts